# Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

> **NCT00326469** · PHASE2 · COMPLETED · sponsor: **Ipsen** · enrollment: 30 (actual)

## Conditions studied

- Neuroendocrine Tumours

## Interventions

- **DRUG:** lanreotide (Autogel formulation)

## Key facts

- **NCT ID:** NCT00326469
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00326469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00326469, "Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00326469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*